Examkin

Soru

Zorluk: ZorGynecologic Infections

A 34-year-old woman comes to the office to establish care. Her primary concern today is an intense, burning vaginal itch accompanied by a thick, white discharge that began five days ago. She is particularly distressed because this marks her fourth identical presentation in the past ten months. She notes that during each of the three prior occurrences, a clinician at a local urgent care prescribed a single antifungal tablet that provided complete relief within days, only for the symptoms to return a few months later. Her medical history is significant for type 2 diabetes mellitus, and her most recent hemoglobin A1c was 8.4%. On pelvic examination, there is marked erythema and edema of the vulva and vagina, with adherent, curd-like discharge in the vaginal vault. The vaginal pH is 4.2. A wet mount preparation with 10% potassium hydroxide reveals abundant budding yeast and pseudohyphae. Which of the following is the most appropriate pharmacologic management strategy for this patient?

  1. Oral fluconazole every 72 hours for three doses, followed by weekly oral fluconazole for 6 monthsCevap
  2. B
    Single dose of oral fluconazole for the patient and empirical oral fluconazole for her sexual partner
  3. C
    Oral fluconazole every 72 hours for two doses, with no further maintenance therapy
  4. D
    Intravaginal boric acid capsules daily for 14 days
  5. E
    Intravaginal metronidazole gel daily for 5 days

Cevap

Oral fluconazole every 72 hours for three doses, followed by weekly oral fluconazole for 6 months
This patient presents with classical signs and symptoms of vulvovaginal candidiasis (VVC), including intense pruritus, curd-like discharge, normal vaginal pH (4.2), and pseudohyphae on wet mount. Crucially, she reports this is her fourth episode within the past 10 months. Recurrent vulvovaginal candidiasis (RVVC) is strictly defined as four or more symptomatic episodes in a 12-month period. Patients with poorly controlled diabetes mellitus are at an increased risk for RVVC due to hyperglycemia enhancing yeast colonization and adhesion. The standard of care for RVVC involves a mandatory two-phase treatment approach: an induction phase to achieve clinical remission (typically oral fluconazole 150 mg every 72 hours for 3 doses) followed by a suppressive maintenance phase (weekly oral fluconazole for 6 months). Without this prolonged maintenance phase, symptomatic relapse is highly likely in these patients, as evidenced by her history of recurring after single-dose treatments.

Adım Adım Çözüm

1
Identify the primary diagnosis based on clinical presentation and microscopic findings.
Vulvovaginal candidiasis (VVC) confirmed by thick white discharge, severe pruritus, pH of 4.2, and pseudohyphae on the potassium hydroxide preparation.
To establish the baseline infection type before determining severity or chronicity.
2
Classify the VVC episode based on frequency and patient risk factors.
The patient has recurrent VVC (RVVC), defined as 4 or more symptomatic episodes in a 12-month period, likely exacerbated by her poorly controlled type 2 diabetes mellitus.
Management guidelines differ significantly between uncomplicated, severe, and recurrent VVC.
3
Determine the guideline-concordant treatment for RVVC.
Induction therapy with 3 doses of oral fluconazole every 72 hours, followed by a 6-month maintenance regimen of weekly oral fluconazole.
Short-course therapy is insufficient for RVVC; prolonged maintenance is required to suppress the infection and prevent rapid relapse.

Anahtar Kavram

Diagnosis and guideline-concordant treatment of recurrent vulvovaginal candidiasis (RVVC) using an induction and 6-month maintenance antifungal phase.
Bu soruyu puanla

Konular

Gynecologic Infections

Bu konudan daha fazla soru